Itraconazole in the Treatment of Nonfungal Cutaneous Diseases: A Review

Itraconazole has been investigated for its potential in managing advanced basal cell carcinomas (BCCs). Distinct from the antifungal mechanism of inhibiting ergosterol synthesis, the anti-Hh pathway is the main target of BCCs. Hydroxy-itraconazole, a metabolite of itraconazole, also inhibits the Hh pathway [5]. The molecular target of itraconazole is on Smoothened (SMO), a G protein-coupled receptor, but the site is distinct from that of cyclopamine and other SMO antagonists [6], which explains its effect on diseases resistant to currently available SMO antagonists. Itraconazole can be used synergistically with other SMO antagonists to control tumors. In 2010, itraconazole was demonstrated to be a Hh inhibitor in murine medulloblastoma and BCC; this was followed by an increase in the number of clinical human trials on itraconazole in a variety of cancer therapies [5, 7].

Kim et al. conducted an open-label, phase II trial to evaluate the efficacy of itraconazole in suppressing BCCs [8]. In this trial, 29 patients were allocated to two active treatment groups receiving various doses of itraconazole and one placebo-controlled group (Table 2). The results showed a decrease of 45% in cell proliferation (biomarker: ki67), of 65% in Hh pathway activity (biomarker: GLI1 [glioma-associated oncogene homolog 1] mRNA), and of 24% in tumor area among patients treated with itraconazole. Both participants in the placebo-controlled group and patients with a history of previous exposure to vismodegib showed no reduction in tumor size, cell proliferation, or Hh pathway activity. This trial confirmed the anti-BCC activity of itraconazole in humans; however, the optimal itraconazole dosing regimen, long-term outcome, and efficacy compared to vismodegib still need further investigation [8].

In a published case series, six infants aged 2–5 months old were treated successfully with oral itraconazole 5 mg/kg per day for their infantile hemangioma. The treatment period was 2–9 weeks, and the mean follow-up time was 9.7 months. Two of the patients had local ulcers and secondary candida infection on the hemangioma lesion. All patients experienced at least partial response in the first month and significant improvement after 3 months. Few adverse events were detected, with only two cases of mild diarrhea which subsided without drug cessation [11].

Okada et al. reported three cases of keloids (n = 2) and hypertrophic scar (n = 1); all three patients showed dramatic improvement following oral itraconazole therapy for 2–4 weeks for the treatment of onychomycosis and tinea pedis [12]. These authors reported that the efficacy of itraconazole might be attributed to the relationship between keloids and fungal infection. On the other hand, Chui et al. proposed that the possible mechanism was based on inhibition of fibroblast growth factors and VEGFs which are involved in the pathogenesis of keloids and hypertrophic scars [13].

One anecdotal report (n = 7) and another single, active-arm study (n = 6) demonstrated itraconazole as an effective treatment for palmoplantar pustulosis (PPP). In both studies, all patients experienced complete resolution of pustules after taking itraconazole 100 mg/day for 2 weeks. Erythema and desquamation improved either modestly or significantly. However, all patients showed a relapse of all lesions within 1 month of discontinuation of itraconazole. Thus, a maintenance dose of 50 mg/day, 100 mg every other day, or 100 mg/50 mg alternatively was administered in some patients until stable remission was achieved. There were no adverse events noted. A possible mechanism of itraconazole in PPP is the anti-inflammatory effect. Specifically, itraconazole inhibits neutrophil chemotaxis, interleukin-8 production, and the formation of pro-inflammatory metabolites (i.e., 5-lipoxygenase) [14, 15].

A single-arm, open trial enrolled 28 patients with human immunodeficiency virus-associated eosinophilic folliculitis [16]. Of these 28 patients, 61% had complete clearance within 2 weeks, and 14% experienced partial response. The initial itraconazole dose was 200–400 mg/day for 2 weeks; if the optimal condition was not achieved, the dose of 200 mg/day was increased to 400 mg/day. In this trial, three patients were shifted to fluconazole due to adverse events or cryptococcal infection; none of them showed improvement. The authors speculated that the reason itraconazole was effective but fluconazole was not might be due to the anti-inflammatory effect of itraconazole rather than to its antifungal effect [16].

Libow et al. were the first to report the use of itraconazole to treat lichen planus (LP) in 1998 [18]. Of the four patients in their study, two experienced complete clearance of lesions following the initiation of itraconazole treatment and two had partial response [17]. In 2009, Khandpur et al. recruited 16 patients with eruptive extensive LP to verify itraconazole as an alternative treatment for this form of LP [18]. This prospective, open-label study was designed to give pulsed oral itraconazole 200 mg twice daily for 1 week in each month to the patients. After 3 months, the results showed that itraconazole was very effective in treating eruptive LP. New lesions ceased to develop in 77.77% of subjects, 55.55% of patients showed alleviation of pruritus, and 33.33% of patients showed a complete flattening of lesions within 3 months [18].

Tercelj et al. designed a single-arm, interventional study to which they recruited 18 patients with stage II or III sarcoidosis to receive antifungal agents (itraconazole, fluconazole, or ketoconazole 200 mg/day) together with corticosteroid (at usual dose, as mentioned in the article) treatment for 3–6 months [19]. Patients who had previously received prednisolone 12 mg or 16 mg every other day for at least 6 months with poor clinical improvement or who had a sarcoidosis relapse after discontinuation of corticosteroid therapy were enrolled in this study. The results revealed a highly significant reduction in pulmonary infiltration based on X-ray scores, significant amelioration in diffusion capacity, and significant improvement in the severity of symptoms, including cough, dyspnea, chest pain, and persistent fever of > 37 °C. The mechanism was reported to be associated with an unknown immune effect. Because no fungi were identified in the lung biopsy, the authors suggested that the antifungal medications used to treat sarcoidosis do not work directly on the synthesis of the fungal cell membrane [19]. However, the use of itraconazole in cutaneous sarcoidosis treatment has not yet been reported.

A good response to itraconazole 200 mg/day for 7 days was reported in a patient with pathology-confirmed plaque-stage mycosis fungoides [20]. Lesions completely subsided within 1 week. The lesions relapsed in the following and third years but again cleared within 1 week of itraconazole therapy. The authors proposed that the possible mechanism is related to the immunomodulatory activity of itraconazole [20]. In previous studies, itraconazole was proven to inhibit T-lymphocyte proliferations in vitro [21] and to have anti-inflammatory effects in vivo [22].

Various studies have revealed that the potency of azole antifungal agents, especially itraconazole, in suppressing T-lymphocyte proliferation is similar to that of cyclosporine, but that interferon-γ and tumor necrosis factor-α were not significantly blocked by azole agents [21, 23]. It has been suggested that the phenylpiperazine ring of itraconazole contributes to the anti-inflammatory activity [24]. The immunosuppressive effect might explain the treatment efficacy of itraconazole in inflammatory diseases such as mycosis fungoides and LP.

A 27-year-old woman diagnosed with yellow nail syndrome unexpectedly experienced better ungual regrowth after itraconazole pulse therapy (400 mg/day, 1 week per month) was added to her vitamin E (800 IU per day) therapy for secondary onychomycosis [25]. The initial 6 months of treatment with vitamin E alone showed only mild improvement of proximal nail growth. After 4 cycles of combined itraconazole and vitamin E therapy, the finger nails improved considerably [25]. The mechanism probably involved the acceleration of nail growth rate by itraconazole, an effect which has been observed in a number of in vivo studies. Doncker et al. found higher nail peaks and a larger mean roughness value, indicating that itraconazole had induced a quicker nail matrix turnover rate, as noted by optical profilometry [26].

However, another eight-case report demonstrated no apparent effect of itraconazole on yellow nail syndrome. In that study, oral itraconazole was administered 400 mg/day, 1 week every month, for at least 6 months. If the nails showed improvement, the treatment time was extended to 12 months. Of the eight patients two were cured and another two showed slight improvement; no improvement was observed for the remaining four patients, and one of these even improvedr after the therapy was changed vitamin E 1200 mg/day for 6 months [27].

One retrospective study involving 24 patients with HND reported that 17 of the patients (71%) responded to a 2-month-long treatment with an oral azole antifungal [28]. All patients were treated with itraconazole 200 mg/day at the start of the treatment regimen, but six were subsequently switched to fluconazole 200 mg/day or ketoconazole 200 mg/day due to healthcare insurance or cost issues. However, a high discontinuation rate during pulse therapy with ITZ 200 mg twice weekly (maintenance phase) suggested that the cephalic type of atopic dermatitis might be induced by hypersensitivity of the Malassezia species rather than by the mere overgrowth of yeasts as occurs in seborrheic dermatitis or tinea versicolor. The authors inferred that because only a small amount of allergen could induce a prolonged hypersensitivity reaction, the twice-weekly regimen during the maintenance phase might lead to dose insufficiency that was unable to control the HND [28].

One randomized controlled trial (RCT) (n = 53 patients) revealed the significant efficacy of a 7-day-long therapeutic regimen of itraconazole at both 200 and 400 mg/day compared with placebo in patients with HND. Regardless of prick tests to Malassezia antigens, itraconazole clearly improved the SCORAD index. However, other areas of body surface showed no significant improvement by global evaluation [29].

Ikezawa et al. conducted a cross-over RCT which recruited 34 subjects with refractory atopic dermatitis and a positive radioallergosorbent test (RAST) to Malassezia [30]. The subjects were distributed into two groups (A and B). Group A was given itraconazole + Lactobacillus preparation for 8 weeks, then the Lactobacillus preparation alone for the following 8 weeks. Group B was given the Lactobacillus preparation alone for 8 weeks, then a combination of itraconazole + Lactobacillus preparation for the following 8 weeks. The dosage of itraconazole was 100 mg/day in both groups. The results revealed that eosinophil counts, serum immunoglobulin E (IgE) levels, specific IgE titers to Malassezia, and the potency or dose of concomitant topical steroids had all declined significantly at the end of the itraconazole treatment in group A and group B [30].

For the treatment of chronic atopic dermatitis [31], Sugita et al. proposed a regimen of itraconazole 100 mg/day for 1 week, followed by itraconazole 200 mg/week for a further 11 weeks. These authors reported that at least 3 months of treatment were required to reduce recurrence for chronic atopic dermatitis.

A double-blind, randomized, placebo-controlled study (n = 137 subjects) reported that the elimination of Malassezia by itraconazole 100 mg/day for 8 weeks significantly reduced the irritation caused by the calcipotriol solution during the treatment of scalp psoriasis (local skin irritation: 19.4% [itraconazole] vs. 47.1% [placebo]; p < 0.001) [32].